Promoting Excellence in Education, Research,
and Patient Care in the Rapidly Evolving
Management of Gastrointestinal Cancer
International Society of
Gastrointestinal Oncology
isgioEstablished 2003
Save the Date for the ISGIO 2017 Conference
The 2018 Gastrointestinal Oncology Conference
The 2018 Gastrointestinal Oncology Conference, the official meeting of the International Society of Gastrointestinal Oncology, will take place November 1-2, 2018 at the Hilton Crystal City in Arlington, VA and will provide an educational forum for presenting and discussing the latest advances in the broad field of GI cancer research, as well as critical issues relevant to the care of persons with GI cancer.

Registration is now open!
2018 Gastrointestinal Oncology Conference
Program Description
The conference will feature distinguished speakers covering a broad spectrum of topics ranging from basic science to clinical therapeutics. Presenters and discussants will explore current issues and debate controversial topics. Case presentations will be given by the faculty and the audience will participate by an interactive audience response system to stimulate discussion on diagnosis and management. This program should be of interest to professionals actively engaged clinically or scientifically in all facets of GI cancer research and care, including oncologists, surgeons, radiologists, general scientists, fellows, young investigators, nurses and pharmacists.
 
Educational Objectives
After attending this activity, the participant will demonstrate the ability to:
b Identify recent advances and innovations in the treatment of GI malignancies within the past 12 months
b Describe emerging evidence from current clinical trials that may impact treatment decision making in GI oncology
b Formulate a multi-modal approach to the treatment of GI cancers including Gastric, HCC, Cholangiocarcinoma, Pancreatic and Colorectal Cancers
b Analyze how recent clinical trial data demonstrate a significant survival benefit with a combination chemotherapy regimen in patients with metastatic pancreatic cancer
b Assess how new developments in treating advanced pancreas adenocarcinoma may help guide post surgical treatment strategies
b Define which patients will benefit from sequencing strategies of anti-EGFR and anti-VEGF therapies, for all patients with normal KRAS, regardless of BRAF status (based on 2 large prospective randomized trial)
b Discuss the multi-center trial results that demonstrate that sunitinib, a multi-targeted TKI may delay disease progression in patients with pancreatic neuroendocrine tumors and contribute to increased survival
b Utilize the prognostic value of 8 molecular markers on relapse-free survival and stages II and III colon cancer.
b Define the benefit for specific subgroups of stage III colon cancer with only 3 months of adjuvant chemotherapy (rather than the standard 6 months).
 
CME Accreditation and Designation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Memorial Sloan Kettering Cancer Center and the International Society of Gastrointestinal Oncology. Memorial Sloan Kettering Cancer Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Memorial Sloan Kettering Cancer Center designates this live activity for a maximum of 12.25 AMA PRA Category 1 Credit(s).
Physicians should claim only the credit commensurate with the extent of their participation in the activity.